Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regeneron Wades Deeper Into Oncology With Ambitions To Be A Force In The Space

Executive Summary

Senior VP-global clinical development David Weinreich addresses the company's growing investment in oncology drug development, why Regeneron is well positioned to lead in the area, and business development.

You may also be interested in...



Regeneron Takes Full Libtayo Rights As March Into Oncology Progresses

The company will pay $900m upfront to buy Sanofi's stake in the PD-1 inhibitor, which is a cornerstone of Regeneron's strategy to build an oncology portfolio.

Regeneron Follows REGEN-COV Revenue Success With Impressive PD-1 Data

Regeneron reported $2.76bn in revenues from the sale of its COVID-19 antibody cocktail, and that Libtayo in combo with chemotherapy was effective in NSCLC.

Regeneron Pipeline Progresses On Several Fronts Despite COVID-19 Focus

Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC141620

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel